The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma.
 
Ritesh R. Kotecha
Consulting or Advisory Role - Eisai; Eisai; Guidepoint Inc; Guidepoint Inc
Research Funding - Allogene Therapeutics (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Xencor (Inst)
 
Sahil D Doshi
No Relationships to Disclose
 
Andrea Knezevic
Consulting or Advisory Role - ByHeart
 
Rachel Jacobi
No Relationships to Disclose
 
David H Aggen
Consulting or Advisory Role - Alphasights; Aptitude Health; Astellas Pharma; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Guidepoint Global Advisors; MJH Life Sciences; Seagen
Patents, Royalties, Other Intellectual Property - University of Illinois - Urbana Champaign
 
Deaglan Joseph McHugh
Honoraria - OncLive
Consulting or Advisory Role - Progenics
 
Neil J. Shah
Honoraria - MedNet, LLC; MedNet, LLC; MJH Life Sciences
Consulting or Advisory Role - Exelixis; Graticule; Merck Sharp & Dohme Corp.
Research Funding - Aravive (Inst); Exelixis
Travel, Accommodations, Expenses - Merck
 
Marie Isabel Carlo
Honoraria - OncLive/MJH Life Sciences; OncLive/MJH Life Sciences
Other Relationship - Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Niamh M. Keegan
No Relationships to Disclose
 
Yogini Gayadin
No Relationships to Disclose
 
Joshua Chaim
No Relationships to Disclose
 
Darren R. Feldman
Consulting or Advisory Role - BioNTech; Renibus Therapeutics; Telix Pharmaceuticals; Xencor
Research Funding - Bristol-Myers Squibb/Roche; Decibel Therapeutics (Inst); Exelixis; Telix Pharmaceuticals
Other Relationship - UpToDate
 
Robert J. Motzer
Consulting or Advisory Role - Aveo; EMD Serono; Exelixis; Incyte; Merck; Takeda
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Martin H Voss
Stock and Other Ownership Interests - CellGenix (I)
Consulting or Advisory Role - Affimed Therapeutics; AVEO; Eisai; Exelixis; Genentech; Merck; MicuRx Pharmaceuticals; Oncorena
Research Funding - Pfizer
(OPTIONAL) Uncompensated Relationships - Aravive; AstraZeneca; AstraZeneca; BMS; Genentech/Roche